Keywords: Medivation, Astellas, MDV3100, Prostate cancer

Strong data from MDV3100 prostate cancer trial lead Medivation and Astellas to stop study early

Article | 04 November 2011

USA-based Medivation (Nasdaq: MDVN) saw its shares rocket 120% to $36.51 in early trading yesterday, after it announced, along with partner Japanese ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Medivation

Astellas Pharma

Go to company listing